MTOR and cancer: The US FDA has approved several antiangiogenic agents for cancer treatment; these include monoclonal antibodies [40] that target specific proangiogenic growth factors and their receptors (ramucirumab and bevacizumab), tyrosine kinases inhibitors (TKIs; axitinib, sunitinib, sorafenib, regorafenib, cabozantinib, pazopanib, and vandetanib) and inhibitors of mammalian target of rapamycin (mTOR; everolimus and temsirolimus).